Development

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

Retrieved on: 
Thursday, January 12, 2023
University of Bedfordshire, Development, Executive, Élan, University, Doctor of Philosophy, Third Point Management, City University, IPO, Inflammation, Knowledge, Psoriasis, Ulcerative colitis, Research and development, Marketing, Economics, Growth, Patient, Genentech, PIPE, Cranfield University, Pfizer, Chemistry, Ionis Pharmaceuticals, MBA, Chicago (franchise), Amylin Pharmaceuticals, Pharmaceutical industry, Management, Biotechnology, Research, Ionis, Science

Dr. Allison Hulme currently serves as Chief Executive Officer, President and a board member of Aeovian Pharmaceuticals.

Key Points: 
  • Dr. Allison Hulme currently serves as Chief Executive Officer, President and a board member of Aeovian Pharmaceuticals.
  • Prior to this, she served as Chief Operating Officer, Head of Research and Development and a board member at Sophiris Bio.
  • Ms. Onaiza Cadoret-Manier currently serves as Executive Vice President, Chief Global Product Strategy and Operations officer at Ionis Pharmaceuticals.
  • “Allison and Onaiza’s deep industry experience and commercialization expertise will be an invaluable addition to our board of directors.

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Retrieved on: 
Thursday, January 12, 2023
Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, Finan of Lindisfarne, World Health Organization, Development, Fever, U.S. Department of Commerce Office of Security, Administration, Ebola, Human services, Vaccine, Sabin Vaccine Institute, Partnership, Death, BARDA, ASPR, United States Department of Health and Human Services

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

Key Points: 
  • There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.
  • These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.
  • The country declared the Ebola Sudan outbreak had ended on January 11 , four months after the first confirmed case.
  • “Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan.

Latch Announces Executive Leadership Changes

Retrieved on: 
Wednesday, January 11, 2023
Transport, Partner, Latcho Drom, Sustainability Accounting Standards Board, Accounting, CFO, Work, Development, AlixPartners, LTCH, Growth, Acquisition, Software as a service, Management, Latch

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Latch, Inc. (NASDAQ: LTCH) (“Latch” or the “Company”), maker of LatchOS, the full-building enterprise software-as-a-service (SaaS) platform, today announced that its Board of Directors (the “Board”) has appointed Jason Keyes as interim Chief Executive Officer and Marc Landy as interim Chief Financial Officer.

Key Points: 
  • NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Latch, Inc. (NASDAQ: LTCH) (“Latch” or the “Company”), maker of LatchOS, the full-building enterprise software-as-a-service (SaaS) platform, today announced that its Board of Directors (the “Board”) has appointed Jason Keyes as interim Chief Executive Officer and Marc Landy as interim Chief Financial Officer.
  • Latch also announced the resignations of Luke Schoenfelder as the Company’s Chief Executive Officer and Chairman of the Board, as well as interim Chief Financial Officer Barry Schaeffer and Chief Accounting Officer Junji Nakamura.
  • Mr. Schoenfelder said, “From co-founding Latch at my kitchen table to leading it to its current scale, I am enormously proud of the products we’ve delivered for customers, and I am excited to continue to support Latch’s new leadership team as a proud stockholder and advisor going forward."
  • The Board also thanks Barry and Junji for their thoughtful leadership and their many contributions to Latch’s growth.

PCCA Introduces Innovative New Compounding Base – SuspendIt® Anhydrous

Retrieved on: 
Wednesday, January 11, 2023
Viscosity, API, Development, PCCA, Bassani, Solubility, Water, Agitation, Growth, Patient, Patent, Bud, Pharmacy, Medicine, Operation, Taste, Quality control, Risk management, Research

“An anhydrous base offers many benefits to compounding pharmacies,” PCCA Chief Scientific Officer Gus Bassani said.

Key Points: 
  • “An anhydrous base offers many benefits to compounding pharmacies,” PCCA Chief Scientific Officer Gus Bassani said.
  • “We developed a unique anhydrous base that, in addition to the self-emulsifying properties, has an improved viscosity, which reduces when shaken and thickens when standing.
  • The technology is so unique that we have a patent pending.”
    Developing the unique anhydrous base was a collaborative effort.
  • Additionally, PCCA has created formulas for the most commonly prescribed APIs and plans to continue formula development and API testing.

GAINS 2022 Innovation Contest Winners Unveiled

Retrieved on: 
Wednesday, January 11, 2023
China Adolescents Science & Technology Innovation Contest, Innovation, DNA, Amazon, Creativity, R, Product management, Professional services, Management, Development

CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- GAINS , a leading provider of innovative cloud-based supply chain planning solutions, announced the winners of its 2022 Innovation Contest.

Key Points: 
  • CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- GAINS , a leading provider of innovative cloud-based supply chain planning solutions, announced the winners of its 2022 Innovation Contest.
  • The GAINS committee selected "Team Mariposa" as the winner for their concept and prototype improving GAINS' integration with omnichannel partners, including Amazon.
  • "Innovation is in the DNA of the GAINS team members, and this year's contest submissions showed our teams' talent, creativity, and passion," said Joe Olson, CEO of GAINS.
  • "The Innovation Contest is a way for our teams to collaborate across departments and think out-the-box, bringing forward new ideas based on their customer interactions, industry expertise, and diverse backgrounds.

THE GAP, INC. (NYSE: GPS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against The Gap, Inc. (NYSE: GPS)

Retrieved on: 
Tuesday, January 10, 2023
News, The Gap, The Wall Street Journal, Gap, District court, Old Navy, NYSE, Development, Woman, Labour government, Court, Sonia Syngal, Advertising, Investment, The Legal 500, Gap Inc., GPS, Tobacco, Security (finance), Athleta

NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of The Gap, Inc. (“Gap” or the “Company”) (NYSE: GPS) between November 24, 2021 and July 11, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Eastern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Eastern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • The Company offers apparel, accessories, and personal care products for men, women, and children under the Old Navy, Gap, Banana Republic, and Athleta brands.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Worksport CEO Steven Rossi Reflects on 2022 and Looks Forward to 2023, aiming for 2023 Profits

Retrieved on: 
Tuesday, January 10, 2023
Information technology, Foot, Intellectual property, EVS, Learning, Sustainable energy, Mathematics, Government, Family, The, EBay, Development, OEM, Complex system, Partnership, Research, Hard, New Year, Interview, Original equipment manufacturer, Electric vehicle, COR, Hyundai, AS/RS, The Home Depot, Renewable energy, Northeast Bank, Q3, MITACS, Amazon

Richmond Hill, Ontario, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- As Worksport’s CEO, let me begin by wishing everyone a Happy and Healthy 2023.

Key Points: 
  • Richmond Hill, Ontario, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- As Worksport’s CEO, let me begin by wishing everyone a Happy and Healthy 2023.
  • It’s an exciting project that moved forward greatly during the rest of the year.
  • It takes time to build the factory to produce electric pickups, regular truck beds and solar covers.
  • We publicly announced this project in a press release on April 21, 2022.

The Gap, Inc. (GPS) Class Action Notice: Contact Robbins LLP for Information Regarding the Class Action Against The Gap, Inc.

Retrieved on: 
Monday, January 9, 2023
News, The Wall Street Journal, Gap, Gap Inc., NYSE, Development, Deception, Complaint, Old Navy, GPS, Security (finance)

What Now: Similarly situated shareholders may be eligible to participate in the class action against Gap.

Key Points: 
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Gap.
  • Shareholders who want to act as lead plaintiff for the class must file their papers by February 3, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • On this news, Gap's stock price fell 5%, to close at $8.32 per share on July 12, 2022.

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Retrieved on: 
Monday, January 9, 2023
IND, Disease, Partner (business rank), Echocardiography, PRISM, Clinical trial, Heart, Dialysis, A101, MD, GA, M.A, Degenerative disease, CF, Initiation, University of Nevada, Reno, Biopsy, Interim, NIH, QOL, University, IHC, Cystic fibrosis, Kidney, AMD, Toxic leukoencephalopathy, Intravitreal administration, RNA, Drug discovery, MRI, Choroideremia, Real-time, GMP, Stanford University School of Medicine, Development, Ahus, Fabry disease, Geographic atrophy, FDA, Retinitis pigmentosa, KCCQ, Addition, Atypical hemolytic uremic syndrome, Fabry, Principal, Ophthalmology, VG, Pulmonology, Enzyme replacement therapy, CFTR, DME, Clinical research, Safety, Diabetic retinopathy, ISH, Modulation, Pharmaceutical industry, Vaccine, 3D printing, Medical imaging, Patient

The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.

Key Points: 
  • The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.
  • It is estimated that there are over one million individuals with GA in the United States according to published data.
  • In addition, I’m excited by the potential of 4D-175, the new preclinical product candidate utilizing the same R100 vector.
  • Cardiac clinical endpoint data (MRI, echocardiography, cardiopulmonary exercise testing [CPET] and QOL assessment) from evaluations at baseline and 12 months after treatment were assessed.

Proteros receives minority investment from private equity firm Inflexion

Retrieved on: 
Monday, January 9, 2023
Gesellschaft mit beschränkter Haftung, Negotiation, Biotechnology, Development, Partnership, Strategic business unit, Marketing, Growth, LLP, Mylab Discovery Solutions, Financial services, Cryptocurrency, Protein, Pharma, Dodi Protero, Inflection

MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.

Key Points: 
  • MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.
  • Inflexion is a leading mid-market private equity firm which works in partnership with ambitious management teams of high growth, entrepreneurial businesses to accelerate sustainable growth.
  • Funds advised by Inflexion Private Equity Partners LLP have funds under management of c.£7.1bn.
  • Dr. Torsten Neuefeind, founder and CEO of Proteros, said: “I am excited to have Inflexion on board as a partner.